Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 11/20 | 0.47 |
| ▸ | LTA4H | P09960 | 3/20 | 0.37 |
| ▸ | CDK1 | P06493 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13865978 | 0.92 | CDK4 (0.46) | CDK4CDK1CDK2CDK6GSK3B | |
| SCHEMBL13866000 | 0.91 | CDK4 (0.54) | CDK4CDK1CDK2CDK6GSK3B | |
| SCHEMBL13866042 | 0.85 | CDK4 (0.48) | CDK4LTA4HCDK1CDK2CDK6 | |
| SCHEMBL13866039 | 0.84 | CDK4 (0.48) | CDK4LTA4HCDK1CDK2CDK6 | |
| SCHEMBL13866038 | 0.84 | CDK4 (0.48) | CDK4LTA4HCDK1CDK2CDK6 | |
| SCHEMBL13866035 | 0.84 | CDK4 (0.48) | CDK4LTA4HCDK1CDK2CDK6 | |
| SCHEMBL13866025 | 0.84 | CDK4 (0.46) | CDK4LTA4HCDK1CDK2CDK6 | |
| SCHEMBL13865991 | 0.81 | CDK4 (0.45) | CDK4LTA4HCDK1CDK2CDK6 | |
| SCHEMBL13866004 | 0.77 | CDK4 (0.50) | CDK4CDK1CDK2CDK6GSK3B | |
| SCHEMBL13865990 | 0.77 | RAB9A (0.33) | CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137597-A1 | Novel quinoxalinone derivatives | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7388010-B2 | Quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-17 | — | — | US | disclosed |
| US-7388010-B2 | Quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | NDUFB1, NDUFB6, NDUFB7 | CDK4 2691/4885LTA4H 2162/4885CDK1 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.